Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system

Drake, Mary; Ranaghan, L.; Morris, T. C. M.; Nolan, Luke; Desai, Z. R.; Irvine, A.; Jordan, A.; Magill, K.; Price, Susan

doi:10.1046/j.1365-2141.1997.2743091.x

Cited by 78 publications

(86 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progenitor cell mobilization is known to be negatively affected by the number of chemotherapy cycles before PBPC mobilization, pelvic radiotherapy and age. 22,25 The higher mobilization potency of CY+G-CSF observed in a patient population that had been pre-treated with a significantly higher number of chemotherapy cycles as compared to patients mobilized with G-CSF alone, strongly suggests that the priming regimen by itself was determinant in the recruitment of higher amounts of primitive and committed progenitors. Differences in pre-mobilization treatment were only likely to determine the strong inter-patient variability observed in hematopoietic progenitor cell harvests.…”

Section: Discussionmentioning

confidence: 99%

CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF

Cesana

Carlo‐Stella

Regazzi

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Mobilized peripheral blood progenitor cells (PBPC) are increasingly used as an alternative to bone marrow for autografting procedures. Currently, cyclophosphamide (CY) followed by granulocyte colony-stimulating factor (G-CSF) or G-CSF alone are the most commonly used PBPC mobilization schedules. In an attempt to investigate whether the use of these two mobilization regimens could result in the collection of functionally different CD34 ؉ cells, we analyzed nucleated cells (NC), CD34 ؉ cells, committed progenitor cells and long-term culture initiating-cells (LTC-IC) in 52 leukaphereses from 26 patients with lymphoid malignancies, mobilized either by CY+G-CSF (n ‫؍‬ 16) or G-CSF alone (n ‫؍‬ 10). Thirty-four aphereses from the CY+G-CSF group and 18 aphereses from the G-CSF group were investigated. According to the study design, leukaphereses were carried out until an average number of 7 ؋ 10 6 CD34 ؉ cells/kg body weight were collected. The mean (؎ s.e.m.) numbers of CD34 ؉ cells mobilized per apheresis by CY+G-CSF and G-CSF were not significantly different (2.76 ؎ 0.6 ؋ 10 8 vs 2.53 ؎ 0.4 ؋ 10 8 , P р 0.7). This resulted from a mean number of NC that was significantly lower in the CY+G-CSF products than in the G-CSF products (12.4 ؎ 1.7 ؋ 10 9 vs 32 ؎ 5.4 ؋ 10 9 , P р 0.0001) and a mean incidence of CD34 ؉ cells that was significantly higher in the CY؉G-CSF products than in the G-CSF products (2.9 ؎ 0.6% vs 0.9 ؎ 0.2%, P р 0.0018). The mean (؎ s.e.m.) number of CFU-GM collected per apheresis was significantly higher in the CY+G-CSF group than in the G-CSF group (37 ؎ 7 ؋ 10 6 vs 14 ؎ 2 ؋ 10 6 , P р 0.03). Interestingly, CY+G-CSF-mobilized CD34 ؉ cells had a significantly higher plating efficiency than G-CSF-mobilized CD34 ϩ cells (25.5 ؎ 2.9% vs 10.8 ؎ 1.9%, P р 0.0006). In addition, the mean number of LTC-IC was significantly higher in the CY+G-CSF products than in the G-CSF products (6.3 ؎ 1 ؋ 10 6 vs 3.3 ؎ 0.3 ؋ 10 6 , P р 0.05). In conclusion, our data provide evidence that CY؉G-CSF and G-CSF induce the mobilization of CD34 ؉ cells with

show abstract

Section: Discussionmentioning

confidence: 99%

CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF

Cesana

Carlo‐Stella

Regazzi

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12] Nonetheless, the former drug is far from being harmless to the bone marrow. 8,13 Lee et al 13 found prior treatment with cisplatin to be a significant independent factor predicting worse HPC collection.…”

Section: Discussionmentioning

confidence: 99%

A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients

Pérez‐Calvo

Fernández

Aristu

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Several reports have sought to define parameters associated with a successful PBSC harvest, and factors such as previous chemotherapy, 4,18,19,20 age, 18 and the mobilization procedure 21 were singled out as relevant. A history of extended field radiotherapy was, as expected, also found to profoundly and constantly affect PBSC collection.…”

Section: Discussionmentioning

confidence: 99%

“…The estimated successful PBSC collection rates exceeded 80% in patients with a score ranging from 0 to 15 and were below 20% in patients with a score greater than 25 ( Figure 1). This scoring system allowed three groups to be defined, one with a low (score 0-15), one with an intermediate (score [16][17][18][19][20][21][22][23][24] and the other with a high (score Ͼ25) probability of unsuccessful PBSC harvest.…”

Section: Bone Marrow Transplantationmentioning

confidence: 99%

Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice

Vantelon

Koscielny

Brault

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Fifty-six patients with chemosensitive NHL were studied to assess factors affecting mobilization and peripheral blood stem cell (PBSC) collection: all were mobilized with high-dose cyclophosphamide and etoposide and G-CSF 5 g/kg/day. None of them had bone marrow involvement at the time of mobilization or a history of extended field irradiation. Previous chemotherapy regimens were divided into two groups: moderately myelotoxic chemotherapy (MMC) and highly myelotoxic chemotherapy (HMC). The adequacy of the PBSC harvest was not associated with age, gender, a past history of bone marrow involvement or disease status. In contrast, the number of MMC cycles (n (MMC) ) and the number of HMC cycles (n (HMC) ) were both significant (P = 0.009 and P = 0.0004, respectively) and were used to compute a score predictive of a successful PBSC harvest: SCORE = n (MMC) + 4 n (HMC) . The estimated successful PBSC collection rate was greater than 80% in patients with a score ranging from 0 to 15 and dropped rapidly to below 20% in patients with a score exceeding 25. This scoring system may help to determine the timing of PBSC mobilization in patients with a score below 15 and suggests that new PBSC mobilization procedures should be investigated in other patients. Bone Marrow Transplantation (2000) 25, 495-499. Keywords: lymphoma; scoring system; peripheral blood stem cell Some patients with poor prognosis lymphoma can now be cured with high-dose chemotherapy followed by hematological stem cell support 1,2 and peripheral blood stem cells (PBSC) accelerate hematological recovery at a faster rate than bone marrow stem cells. 3 Consequently, the surgical bone marrow harvest procedure has progressively been replaced by peripheral blood collection obtained by leukapheresis. Although PBSC mobilization and collection techniques have improved, the yield is still suboptimal in a subset of patients. In particular, heavily pretreated

show abstract

Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system

Abstract: Summary.A quantitative analysis of peripheral blood stem cell (PBSC) yield, measuring absolute numbers of CD34 þ cells × 10 6

Cited by 78 publications

References 7 publications

CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF

CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF

A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients

Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice

Contact Info

Product

Resources

About